Literature DB >> 23774167

The reticulin algorithm for adrenocortical tumor diagnosis: a multicentric validation study on 245 unpublished cases.

Eleonora Duregon1, Ambrogio Fassina, Marco Volante, Gabriella Nesi, Raffaella Santi, Gaia Gatti, Rocco Cappellesso, Paolo Dalino Ciaramella, Laura Ventura, Marcello Gambacorta, Angelo Paolo Dei Tos, Paola Loli, Massimo Mannelli, Franco Mantero, Alfredo Berruti, Massimo Terzolo, Mauro Papotti.   

Abstract

The pathologic diagnosis of adrenocortical carcinoma (ACC) still needs to be improved, because the renowned Weiss Score (WS) system has a poor reproducibility of some parameters and is difficult to apply in borderline cases and in ACC variants. The "reticulin algorithm" (RA) defines malignancy through an altered reticulin framework associated with 1 of the 3 following parameter: necrosis, high mitotic rate, and vascular invasion. This study aimed at validating the interobserver reproducibility of reticulin stain evaluation in an unpublished series of 245 adrenocortical tumors (61 adenomas and 184 carcinomas) from 5 Italian centers, classified according to the WS. Eight pathologists reviewed all reticulin-stained slides. After training, a second round of evaluation on discordant cases was performed 10 weeks later. The RA reclassified 67 cases (27%) as adenomas, including 44 with no reticulin alterations and 23 with an altered reticulin framework but lacking the subsequent parameters of the triad. The other 178 cases (73%) were carcinomas according to the above-mentioned criteria. A complete (8/8 pathologists) interobserver agreement was reached in 75% of cases (κ=0.702), irrespective of case derivation, pathologists' experience, and histologic variants, and was further improved when only those cases with high WS and clinically malignant behavior were considered. After the training, the overall agreement increased to 86%. We conclude that reticulin staining is a reliable technique and an easy-to-interpret system in adrenocortical tumors; moreover, it has a high interobserver reproducibility, which supports the notion of using such a method in the proposed 2-step RA approach for ACC diagnosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23774167     DOI: 10.1097/PAS.0b013e31828d387b

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  20 in total

1.  Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).

Authors:  A Stigliano; I Chiodini; R Giordano; A Faggiano; L Canu; S Della Casa; P Loli; M Luconi; F Mantero; M Terzolo
Journal:  J Endocrinol Invest       Date:  2015-07-14       Impact factor: 4.256

Review 2.  Roles of the pathologist in evaluating surrogate markers for medical therapy in adrenocortical carcinoma.

Authors:  Hironobu Sasano; Fumitoshi Satoh; Yasuhiro Nakamura
Journal:  Endocr Pathol       Date:  2014-12       Impact factor: 3.943

3.  Pathology of the adrenal cortex: a reappraisal of the past 25 years focusing on adrenal cortical tumors.

Authors:  Mauro Papotti; Eleonora Duregon; Marco Volante; Anne Marie McNicol
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

Review 4.  What Did We Learn from the Molecular Biology of Adrenal Cortical Neoplasia? From Histopathology to Translational Genomics.

Authors:  C Christofer Juhlin; Ozgur Mete; Jérôme Bertherat; Thomas J Giordano; Gary D Hammer; Hironobu Sasano
Journal:  Endocr Pathol       Date:  2021-02-03       Impact factor: 3.943

Review 5.  Immunohistochemical Biomarkers of Adrenal Cortical Neoplasms.

Authors:  Ozgur Mete; Sylvia L Asa; Thomas J Giordano; Mauro Papotti; Hironobu Sasano; Marco Volante
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

6.  Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.

Authors:  Beatrice Rubin; Daniela Regazzo; Marco Redaelli; Carla Mucignat; Marilisa Citton; Maurizio Iacobone; Carla Scaroni; Corrado Betterle; Franco Mantero; Ambrogio Fassina; Raffaele Pezzani; Marco Boscaro
Journal:  Tumour Biol       Date:  2016-07-28

7.  Adrenocortical oncocytoma presenting as Cushing's syndrome: an additional report of a paediatric case.

Authors:  Bernardo Dias Pereira; Elisabete Silva Rios; Rafael Adame Cabrera; Jorge Portugal; Luísa Raimundo
Journal:  Endocr Pathol       Date:  2014-12       Impact factor: 3.943

8.  Adrenocortical carcinoma: modern management and evolving treatment strategies.

Authors:  Lucas A McDuffie; Rachel D Aufforth
Journal:  Int J Endocr Oncol       Date:  2016-04-08

9.  Differential Expression Profiles of Cell-to-Matrix-Related Molecules in Adrenal Cortical Tumors: Diagnostic and Prognostic Implications.

Authors:  Marco Volante; Ida Rapa; Jasna Metovic; Francesca Napoli; Cristian Tampieri; Eleonora Duregon; Massimo Terzolo; Mauro Papotti
Journal:  J Pers Med       Date:  2021-05-06

Review 10.  Adrenocortical carcinoma: current state of the art, ongoing controversies, and future directions in diagnosis and treatment.

Authors:  Omair A Shariq; Travis J McKenzie
Journal:  Ther Adv Chronic Dis       Date:  2021-07-20       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.